Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Forecasted Growth Rate and Market Size of the Male Hypogonadism Market?
The market for male hypogonadism has seen significant expansion in the past few years. The projection for growth is from $3.75 billion in 2024 to $3.95 billion in 2025, marking a 5.3% compound annual growth rate (CAGR). Factors such as the aging population, increased awareness and diagnosis options, lifestyle conditions, chronic diseases, and treatment-seeking behavior have contributed to the growth during the historic period.
In the coming years, robust growth is expected in the male hypogonadism market. The market is anticipated to hit “$4.99 billion by 2029, growing at a compound annual rate of 6.0%. Factors contributing to this growth during the forecast period include an increase in awareness, the prevalence of lifestyle-related illnesses, therapy innovations, a focus on men’s health, telemedicine, and accessible healthcare. Future trends projected for this period encompass increased focus on psychological and sexual health, exploration of nutraceuticals and lifestyle interventions, the expansion of the market in emerging economies, collaborative research efforts, and a focus on long-term safety and monitoring.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9969&type=smp
Which Factor Is Shaping The Future Of The Male Hypogonadism Market?
Expectations for the advancement of the male hypogonadism market are bolstered by an uptick in infertility rates. Infertility is a condition where either the male or female reproductive system is impaired, preventing conception after a year or more of regular, unprotected sexual relations. A potential cause of male infertility is male hypogonadism, which can lower sperm production and lead to infertility. Consequently, a rising occurrence of male infertility is predicted to propel the expansion of the male hypogonadism market. For example, as per the Office for National Statistics, a government department in the UK, in February 2024, the total fertility rate (TFR) rose to 1.49 children per woman in 2022, from 1.55 in 2021. Hence, a spike in the infertility rate is stimulating the male hypogonadism market’s growth.
What Is The Segment-Wise Breakdown Of The Male Hypogonadism Market?
The male hypogonadism market covered in this report is segmented –
1) By Type: Klinefelters Syndrome, Kallmann Syndrome, Pituitary Disorders, Other Types
2) By Drug Delivery: Topical Gels, Injectables, Transdermal Patches, Other Drug Deliveries
3) By Therapy: Testosterone Therapy, Gonadotropin-Releasing Hormone Therapy
Subsegments:
1) By Klinefelter’s Syndrome: 47,XXY Syndrome, Other Variants
2) By Kallmann Syndrome: Isolated Kallmann Syndrome, Syndromic Kallmann Syndrome
3) By Pituitary Disorders: Hypopituitarism, Pituitary Tumors, Other Pituitary Disorders
4) By Other Types: Androgen Insensitivity Syndrome, Testicular Dysgenesis Syndrome, Genetic Mutations And Disorders
What Upcoming Trends Are Expected To Impact The Male Hypogonadism Market Globally?
One significant trend gaining traction in the male hypogonadism market is product innovation. To maintain their market standing, businesses in this sector are developing new product offerings. For example, Halozyme, a biotech company from the U.S, introduced Tlando to the market in June 2022. This oral testosterone replacement therapy medication for male hypogonadism is revolutionary being the first of its kind to secure FDA approval. Tlando, which has testosterone as its main ingredient, is utilized to address low or absent testosterone levels in adult men caused by certain medical conditions.
Which Companies Hold The Largest Market Share In The Male Hypogonadism Sector?
Major companies operating in the male hypogonadism market include Pfizer Inc., Bayer AG, Eli Lilly and Company Ltd., Endo International plc., Merck & Co. Inc., Ferring Pharmaceuticals, Finox Biotech AG, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Perrigo Company plc, IBSA Institut Biochimique SA, Sun Pharmaceutical Industries Limited, Glenmark Pharmaceuticals Limited, Antares Pharma Inc., Zydus Cadila LLC, Besins Healthcare Ltd., Clarus Therapeutics Holdings Inc., Foresee Pharmaceuticals Co. Ltd., Lipocine Inc., Myovant Sciences Ltd., Sandoz International GmbH, Shionogi & Co. Ltd., TherapeuticsMD Inc., Viking Therapeutics Inc.
Get The Full Report Here:
https://www.thebusinessresearchcompany.com/report/male-hypogonadism-global-market-report
How Does Regional Performance Compare Across The Male Hypogonadism Industry?
North America was the largest region in the male hypogonadism market in 2024. Asia-Pacific is expected to be the fastest-growing region in the male hypogonadism market report during the forecast period. The regions covered in the male hypogonadism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=9969&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model